Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
NCT01121562
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Pancreatic Neuroendocrine Tumors
Interventions
DRUG:
Sunitinib
Sponsor
Pfizer